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Chronic intranasal treatment with an anti-Aβ(30-42) scFv
antibody ameliorates amyloid pathology in a transgenic
mouse model of Alzheimer's disease
Abstract
Amyloid-beta peptide (Aβ)-directed active and passive immunization therapeutic strategies
reduce brain levels of Aβ, decrease the severity of beta-amyloid plaque pathology and reverse
cognitive deficits in mouse models of Alzheimer's disease (AD). As an alternative approach to
passive immunization with full IgG molecules, single-chain variable fragment (scFv)
antibodies can modulate or neutralize Aβ-related neurotoxicity and inhibit its aggregation in
vitro. In this study, we characterized a scFv derived from a full IgG antibody raised against the
C-terminus of Aβ, and studied its passage into the brains of APP transgenic mice, as well as its
potential to reduce Aβ-related pathology. We found that the scFv entered the brain after
intranasal application, and that it bound to beta-amyloid plaques in the cortex and
hippocampus of APP transgenic mice. Moreover, the scFv inhibited Aβ fibril formation and
Aβ-mediated neurotoxicity in vitro. In a preventative therapeutic approach chronic intranasal
treatment with scFv reduced congophilic amyloid angiopathy (CAA) and beta-amyloid plaque
numbers in the cortex of APPswe/PS1dE9 mice. This reduction of CAA and plaque pathology
was associated with a redistribution of brain Aβ from the insoluble fraction to the soluble
peptide pool. Due to their lack of the effector domain of full IgG, scFv may represent an
alternative tool for the treatment of Aβ-related pathology without triggering Fc-mediated
effector functions. Additionally, our observations support the possibility that Aβ-directed
immunotherapy can reduce Aβ deposition in brain vessels in transgenic mice.
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Abstract
Amyloid-beta peptide (Ab)-directed active and passive immunization therapeutic strategies reduce brain levels of Ab,
decrease the severity of beta-amyloid plaque pathology and reverse cognitive deficits in mouse models of Alzheimer’s
disease (AD). As an alternative approach to passive immunization with full IgG molecules, single-chain variable fragment
(scFv) antibodies can modulate or neutralize Ab-related neurotoxicity and inhibit its aggregation in vitro. In this study, we
characterized a scFv derived from a full IgG antibody raised against the C-terminus of Ab, and studied its passage into the
brains of APP transgenic mice, as well as its potential to reduce Ab-related pathology. We found that the scFv entered the
brain after intranasal application, and that it bound to beta-amyloid plaques in the cortex and hippocampus of APP
transgenic mice. Moreover, the scFv inhibited Ab fibril formation and Ab-mediated neurotoxicity in vitro. In a preventative
therapeutic approach chronic intranasal treatment with scFv reduced congophilic amyloid angiopathy (CAA) and beta-
amyloid plaque numbers in the cortex of APPswe/PS1dE9 mice. This reduction of CAA and plaque pathology was associated
with a redistribution of brain Ab from the insoluble fraction to the soluble peptide pool. Due to their lack of the effector
domain of full IgG, scFv may represent an alternative tool for the treatment of Ab-related pathology without triggering Fc-
mediated effector functions. Additionally, our observations support the possibility that Ab-directed immunotherapy can
reduce Ab deposition in brain vessels in transgenic mice.
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Introduction
Alzheimer’s disease (AD) is the most common form of dementia
in the aged population and the number of patients is continuously
increasing due to a lack of effective treatments. Therefore,
considerable efforts focus on the development of efficacious
therapies [1]. AD is characterized by progressive memory deficits
and cognitive impairments. The histopathological characteristics
are extracellular amyloid deposits and intracellular neurofibrillary
tangles. The accumulation of these protein aggregates is
accompanied by synaptic dysfunction, inflammation and eventu-
ally neuronal death [2]. Generation of the amyloid b- peptide (Ab)
from the amyloid precursor protein (APP) by b- and c-cleavage
followed by seeded aggregation of Ab is widely believed to be the
initiating event in the pathogenesis of AD [3] resulting in sustained
deposition of Ab in brain parenchyma and cerebral blood vessels
[4]. Because Ab aggregates are neurotoxic, numerous strategies to
prevent Ab aggregation and accumulation are currently studied as
potential ways to treat or prevent AD.
Ab immunotherapy was first introduced by Schenk et al. [5],
who demonstrated that vaccination with Ab1-42 and Freund’s
adjuvant not only prevented Ab accumulation in younger
PDAPP mice but also cleared pre-existing amyloid plaques in
older animals. This first study was followed by several preclinical
studies in different transgenic AD mouse models, which
substantiated the therapeutic potential of targeting Ab by active
immunization or passive administration of anti-Ab antibodies
[5,6]. In view of these promising results, animal experiments were
soon followed by a human clinical trial with aggregated Ab1-42
and the QS-21 adjuvant (Elan/Wyeth AN1792 trial). The Phase I
clinical trial demonstrated apparent safety and tolerability of
AN1792, which elicited a significant antibody response to Ab1-42
[7]. A subsequent Phase II clinical trial was halted due to aseptic
meningoencephalitis in 6% of the treated patients [8]. A long-
term follow-up study of the Zurich cohort revealed increased
titers of Ab-specific antibodies [9,10] and a slowed cognitive
decline in patients who had responded to the active vaccine as
compared to non-responders [11]. The cases of meningoenceph-
alitis did not correlate with the presence or concentration of
antibodies to Ab [8,9], and it is now generally believed that the
meningoencephalitis was due to a T-cell response against Ab
[2,12]. Histopathological analysis of brain tissue obtained from
individual patients who had died from unrelated causes revealed
beta-amyloid plaque clearance in association with increased
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antibody titers, with some brain regions virtually free of beta-
amyloid plaques [1].
Because of the adverse side effects of active vaccination, passive
immunization with humanized monoclonal antibodies against Ab is
vigorously pursued as an alternative approach [13,14]. In several
studies it was shown that this therapeutic approach was rather
successful in ameliorating amyloid pathology but that it was not free
of side effects either. Intracerebral hemorrhages associated with
cerebral amyloid angiopathy (CAA) were increased in APP transgenic
mice treated with some antibodies, especially those binding to
amyloid plaques [15,16,17]. Antibody-mediated microhemorrhages
may be related to interactions of anti-Ab antibodies with vascular
amyloid causing structural fragility of degenerated vessel walls [17].
Another possible explanation might be related to Fc effector functions
since de-glycosylated IgG without effector function were still effective
in clearing amyloid plaques, but had a significantly reduced ability to
induce microhemorrhages in transgenic mice [18]. Additionally, it
was shown that antibody therapeutics can lead to increased
inflammatory responses mediated by the Fc domain of full IgG
antibodies. Moreover, Bacskai et al. reported that F(ab)2 fragments
were also capable of removing plaques providing evidence that non-
Fc-mediated mechanisms may be involved in the clearance of beta-
amyloid by passive immunotherapy [19].
In view of these findings, single chain variable fragments (scFv) of
IgG, lacking the Fc effector domain, have evolved as a novel and
promising therapeutic tool for the treatment of AD. ScFvs have a low
molecular weight of less than 30 kDa which might facilitate their
transfer across the blood-brain barrier into the brain. ScFvs consist of
a single polypeptide chain, comprising an antibody heavy chain
variable domain (VH) associated by a flexible polypeptide linker to a
light chain variable domain (VL) [20,21,22]. This construct can easily
be expressed in E. coli [23], rendering scFv production efficient and
cost-effective. Previous in vitro studies demonstrated that scFv were
capable of inhibiting Ab1-42 aggregation and preventing Ab-induced
neurotoxicity [24,25,26,27,28]. In addition, two in vivo studies showed
that scFv can ameliorate amyloid pathology after stereotaxic injection
into the hippocampus and cortex of Tg2576 mice [29] or after
intracranial adeno-associated virus-mediated delivery of an anti-pan
amyloid-beta scFv in TgCRND8 mice [30].
Building on our previous finding that the full IgG 22C4 directed
against the C-terminus of Ab cleared brain amyloid, we tested
whether an antibody fragment derived from 22C4 IgG retained this
activity [31,32]. Therefore we characterized a scFv generated by
grafting the complementarity determining regions (CDRs) of the
VH and VL domains of the 22C4 IgG into a human scFv
framework. The resulting 22C4 scFv was expressed in E. coli and
characterized in terms of its binding characteristics, and its potential
to inhibit Ab aggregation and prevent Ab-induced neurotoxicity.
Finally, we treated 8 month old APPswe/PS1dE9 intranasally with
22C4 scFv, the full IgG 22C4 and a vehicle control, to evaluate the
in vivo efficacy of 22C4 scFv to ameliorate beta-amyloid pathology.
As scFv have a very short half-life after systemic application due to
glomerular filtration we chose the intranasal application as route of
delivery. It is known that peptides enter the brain quickly via the
nasal route, thus circumventing the blood-brain barrier and renal
excretion [33,34,35], although the exact transport routes and
mechanisms of this way of delivery are to date not yet fully
understood [36,37,38,39,40].
Materials and Methods
Generation and production of 22C4 scFv
22C4 scFv is a single chain antibody (scFv) emanating from the
Ab-specific mouse IgG1 antibody 22C4, which was generated by
immunizing mice with Ab30-42. Therefore, both 22C4 IgG and
22C4 scFv are directed against the C-terminus of Ab.
The VL and the VH domains were cloned as published previously
[20,21,23]. Briefly, the mRNA was derived from hybridoma cells
producing the antibody 22C4. An RT-PCR using the primers
described by Burmester and Plu¨ckthun was performed to amplify
the VL and VH domains. The two domains were assembled by a
SOE-PCR (splicing by overlap extension). The amplified scFv
fragment was digested by SfiI, cloned into a pTFT74 expression
vector and sequenced. The mouse scFv antibody obtained had kept
its specificity for Ab1-42. Humanisation of scFv was performed by
grafting the CDRs of the VL and VH domains into a human scFv
framework leading to the single chain antibody 22C4 scFv. For the
control scFv Fw 2.3 random CDRs were grafted into the analogous
framework, which in both cases carries a 5xHis-Tag and a FLAG-
Tag for purification and detection.
Plasmids encoding 22C4 scFv and the control scFv were
introduced into BL21 (DE3) E. coli and expressed as inclusion
bodies. Functional single chain antibodies were obtained by
refolding from inclusion bodies, dialysis and subsequent purifica-
tion by gel filtration over a Superdex S75 16/60 column (GE
Healthcare) which was connected to the A¨kta Basic FPLC System
(GE Healthcare). Production of 22C4 scFv and the control scFv
was done at ESBATech, Schlieren, Switzerland.
Determination of mass
The exact mass of 22C4 scFv was determined by electro spray
mass spectrometry in collaboration with the Functional Genomics
Centre (University of Zurich). 22C4 scFv was purified and measured
in 50 % acetonitrile/0.2 % formic acid (pH 2). Mass spectra (neutral
mass) were deconvoluted using the MaxEnt1 software.
Stability assay
The midpoint of denaturation of 22C4 scFv was determined in
a thermal stability study measuring the Fourier transform-infrared
(FT-IR) spectrum using a Bio-ATR-cell on a Bruker Tensor 27
spectrometer. A temperature ramp ranging from 25 to 95uC with
a 22C4 scFv concentration of 5 mg/ml was performed. 22C4 scFv
was left to equilibrate at each temperature for 1–2 minutes before
the spectrum was measured.
Analytical size exclusion chromatography
Size Exclusion Chromatography (SEC) was performed to verify
the specific binding of 22C4 scFv to Ab1-42, which should elute as
a single peak, indicating that Ab1-42 and 22C4 scFv eluted
together, whereas no binding would lead to two different peaks in
the elution profile. For this purpose FITC- Ab1-42 (Bachem,
Bubendorf, Switzerland) and 22C4 scFv or the control scFv were
preincubated at equimolar concentrations (1 mM) under different
conditions (temperature and time), which all led to the same result.
The gel filtration was performed on a Superdex 75 10/300 column
(GE Healthcare, Munich, Germany), which was connected to the
A¨kta Basic FPLC System (GE Healthcare). 150 ml of each assay
were injected into the column and eluted with filtered and
degassed TBS (pH 7.4). Samples were detected by UV absorbance
(495 nm and 215 nm) at a flow rate of 0.75 ml/min.
BioLayer interferometry
BioLayer Interferometry (BLI) is a label-free technology for
measuring biomolecular interactions. It is an optical analytical
technique allowing for the analysis of the interference pattern of
white light reflected from two surfaces: a layer of immobilized
protein on the biosensor tip, and an internal reference layer. A
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change in the number of molecules bound to the biosensor tip
causes a shift in the interference pattern. Only molecules binding
to or dissociating from the biosensor tip can shift the pattern and
thus, generate a response profile on the Octet Q System (ForteBio
Inc., Menlo Park, CA). The assays were measured in a 96-well
format, where the biosensor tip was moved from well to well for
incubation. For the pre-equilibrium the streptavidin–coated
biosensor tip was incubated in PBS (pH 7.4) for 300 s, the tip
was then loaded with biotinylated-Ab1-42 (250 nM in PBS, pH 7.4)
for 400 s. After washing the tip for 600 s in PBS (pH 7.4), the
association step with 22C4 scFv (200 nM, 125 nM, 75 nM,
50 nM in PBS) or 22C4 IgG (50 nM in PBS) was carried out for
2100 s followed by a dissociation step for 2100 s in PBS. The
assays were analyzed and fitted with the Octet Software 4.0
(ForteBio Inc.).
Cell culture binding assay
Human embryonic kidney 293 (HEK293T) cells (LGC
Standards – ATCC, Molsheim Cedex, France) were cultured in
Dulbecco’s minimum essential medium (DMEM) supplemented
with 10% FCS, 2 mM L-glutamine, HEPES and penicillin/
streptomycin in a humidified atmosphere of 5% CO2 at 37uC.
The cells were plated on fibronectine-coated (Sigma, St. Louis,
MO) four-chamber Culture Slides (BD Biosciences, Bedford, MA)
at a density of 10000 cells/well 24 h before transfection with an
APP-Citrine expressing construct. Another 24 h later, the cells
were incubated for 30 min at 4uC with 6E10 antibody (Covance
Inc., Princeton, NJ), 22C4 scFv, 22C4 IgG and corresponding
controls (Fw 2.3, 2H6C2; all 1:100). After the binding assay the
cells were washed with TBS (pH 7.4) and fixed with 4% PFA for
15 min at RT. For immunocytochemistry the cells were stained o/
n at 4uC with a rabbit anti-His polyclonal antibody (1:500 Abcam,
Cambridge, MA) in case of 22C4 scFv and the control scFv,
followed by detection with an anti-rabbit Cy3 antibody (1:1000).
6E10, 22C4 IgG and 2H6C2 were detected directly with an anti-
mouse Cy3 antibody (1:1000). Slides were incubated with
secondary antibody for 2 h at RT. All washing steps were done
with TBS/0.05% Triton X-100.
Preparation of Ab1-42
Recombinant Ab1-42 peptide was obtained as ultra pure HFIP
film from rPeptide (Bogart, GA) and reconstituted in HFIP, which
was evaporated with a constant stream of nitrogen. The peptide
was then again resuspended in HFIP and aliquoted in Protein
LoBind Tubes (Eppendorf). Again HFIP was evaporated with
nitrogen, the tubes were snap frozen in liquid nitrogen and
aliquots were stored at 280uC.
For experimental use the HFIP film of the peptide was dissolved
in 10 mM NaOH (pH 12), which keeps Ab1-42 in its monomeric
form. After neutralization with an equivalent amount of 10 mM
HCl (pH 2) the aggregation process was started.
Anti-Ab antibody ELISA and competition ELISA
The binding characteristics of 22C4 scFv and the corresponding
full IgG 22C4 were measured by ELISA. For the binding activity
assay, the plate was coated with 1 mg/ml recombinant Ab1-42 or
synthetic Ab1-42. The antibodies were added at concentrations
from 0.001 nM to 10000 nM and incubated on the plate for 1 h at
RT. The scFv was detected with a mouse anti-His antibody (1:500;
Qiagen, Hilden, Germany) and an anti-mouse HRP antibody
conjugate (1:1000, GE Healthcare), the full IgG was directly
detected with the anti-mouse HRP antibody. The absorbance was
measured at 450 nm and 620 nm with a Tecan Sunrise plate
reader (Tecan, Ma¨nnedorf, Switzerland).
For the competition analysis the plate was coated with Ab1-42 as
previously described. 10 nM 22C4 scFv were preincubated with
increasing concentrations of Ab1-42 or scrambled Ab1-42 (0 nM to
1000 nM) for 1 h at 4uC. The preincubated mixtures were added
to the coated ELISA plate for 15 min at RT, after incubation these
mixtures were transferred to another Ab1-42 -coated plate and
treated identically, to confirm that the binding equilibrium was not
disturbed. Both plates were subsequently treated as described for
the anti-Ab antibody ELISA.
Thioflavin T aggregation assay
Inhibition of Ab fibril formation by scFv was monitored by
Thioflavin T (ThT) fluorescence. Recombinant Ab1-42 (in 10 mM
NaOH) was incubated at a concentration of 2.5 mM with 2.5 mM,
1.25 mM or 0.25 mM of 22C4 scFv. The assay was performed with
50 mM ThT, 500 mM NaCl, 0.1 mM HCl and 10 mM sodium
phosphate at 25uC. The assay was stirred throughout the entire
measurement. The fluorescence of four parallel reactions was
measured in a Fluorescence Spectrophotometer (Varian Inc.) at
456.2 nm (Excitation) and 489.4 nm (Emission), every 2 min for
180 min. The assay was performed 3 times.
Cell culture and toxicity studies
For primary rat cortical neuron cultures embryos (E18) were
isolated and brains dissected on ice-cold PBS (pH 7.4)/glucose
(1 mg/ml) according to standard procedures but with minor
changes to the protocol. Briefly, brains were dissected, cortices
removed and collected in ice-cold PBS/glucose. Cortices were
then stripped off the meninges, minced and incubated in Dispase
II (Roche, Indianapolis, IN; 2.4 U/ml) at 37uC for 10 min. The
tissue was washed with DMEM plus 10%FCS, triturated and the
number of living cells was determined after staining with Trypan
Blue. After centrifugation of the cells for 5 min at 1000 rpm and
removal of the DMEM/FCS, cells were resuspended and diluted
to the desired density in Neurobasal medium (Invitrogen,
Carlsbad, CA) supplemented with B27 (Invitrogen) and L-
glutamine (Invitrogen). Cells were then plated on poly-ornithin-
coated (Sigma, St. Louis, MO; 10 mg/ml) 96-well white-walled
optical plates (Nunc, Rochester, NY) at 100000 cells/well.
Cultures were then incubated for 5 d in vitro (DIV) at 37uC and
7% CO2 before the neurotoxicity assay was started. For the assay
recombinant Ab1-42 (preparation see above) and 22C4 scFv were
added directly to the cultures each at a final concentration of
5 mM and 0.5 mM, or were preincubated together for 4 h at 37uC
and 500 rpm shaking before being added to the cells. Controls
were treated with Ultra-Pure H2O for Cell Culture (Invitrogen).
The plates were incubated for 48 h before evaluating neurotox-
icity with the CytoTox-GloTM Cytotoxicity assay (Promega,
Madison, WI). The assay was performed according to the
manufacturer’s protocol. The luminescence was measured with a
SpectraMax GeminiXS plate reader (Molecular Devices, Sunny-
vale, CA). Each treatment group was measured in 12 replicates
and each experiment was repeated 3 times. Data were calculated
as means 6 SD.
Immunohistochemistry and Immunocytochemistry
Five micron paraffin sections of human AD and mouse brain
tissue from APPswe/PS1dE9 [42], APPswe/PS1 [43] and ArcAb
[44] mice were mounted on glass slides and immunohistochem-
istry/immuno-fluorescence was performed; for DAB stainings the
Vector Elite ABC kits (Vector Laboratories, Burlingham, CA)
were used. The following antibodies were used for neuropatho-
logical analyses: 6E10 (1:1000; Covance), anti-GFAP (1:400;
Advanced Immunochemicals, Long Beach, CA), 22C4 scFv
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(1:100), 22C4 IgG (1:500), anti-His (1:100; Abcam, Cambridge,
UK), anti-mouse biotinylated antibody (1:500; Jackson, Suffolk,
UK), anti-guinea pig Cy2 (1:100; Jackson), anti-mouse Cy3
(1:1000; Jackson) and anti-rabbit Cy3 (1:1000; Jackson). Thioflavin
S staining for fibrillar Ab and CAA was performed by incubating
slides in 0.25% KMnO4 for 20 min, followed by incubation in 2%
K2S2O5/1% oxalic acid for 2 min, 0.25% acetic acid for 10 s and
finally in 0.0125% Thioflavin S in 50% ethanol for 3 to 5 min
followed by rinses in 50% ethanol and finally in distilled water.
The Perl’s Prussian blue method was used to visualize ferric iron in
hemosiderin as a measure for microhemorrhages and was
performed as published previously. For quantification of immu-
noreactivity, acquisition of images was performed using the
DotSlide Virtual Slide System (Olympus, Tokyo, Japan). Acqui-
sition time was held constant for all images. Computer-assisted
analysis of images was performed using the Image J software.
Plaque and CAA number was calculated for the cortex area in 5
equidistant saggital sections of all treated animals.
For Immunocytochemistry rat primary cortical neurons were
prepared, cultured and treated according to the protocol for Cell
Culture Toxicity Studies. After treatment the cells were washed
with PBS and fixed with 4% PFA in PBS. For immunofluores-
cence the following antibodies were used: anti-Map2 (1:1000;
Millipore, Billerica, MA), anti- Ab1-42 (1:250; Calbiochem, San
Diego, CA), anti-His (1:1000, Abcam) and anti-Cleaved Caspase 3
(1:100; Cell Signaling Technologies, Danvers, MA). The staining
was repeated three times.
Animals and Intranasal Treatment
Intranasal treatment was performed in 7.5 month-old male and
female APPswe/PS1dE9 mice [42] on a C57BL/6 background,
which were originally obtained from the Jackson Labs (Bar
Harbour, ME). Animals were treated for 14 weeks starting at the
age of 7.5 months, each of the 3 groups contained 15 animals; all
groups were balanced for age gender. Control animals (treated
with PBS, sterile, pH 7.4) and 22C4 IgG-treated animals received
weekly intranasal applications (IgG concentration: 1 mg/ml). The
22C4 scFv-treated group was treated twice a week (scFv
concentration: 1.5 mg/ml). With every application, animals
received drop wise 20 ml of PBS, 22C4 IgG or 22C4 scFv by
alternating between the nares. The application was performed in
awake mice as described by Hanson et al. [45]. Briefly, the animals
were grabbed by the skin of their necks and held firmly in the palm
of the hand to minimize movement. During the total application
time of 5 min each mouse was held in the hand in a supine
position. After the treatment animals were returned to their home
cage. All animal use was approved by the Swiss Institute for
Animal Welfare and was in compliance with all federal and state
regulations (approval ID 202-2005, Kantonales Veterina¨ramt
Zu¨rich).
After the final treatment animals received a lethal dose of
Ketamine/Xylazine and were transcardially perfused with ice-cold
PBS (pH 7.4). Brains were isolated and divided sagitally; one hemi
brain was snap frozen in liquid nitrogen and stored at280uC until
further processing, the second hemisphere was post-fixed in 4%
PFA in PBS, dehydrated and embedded in paraffin for histological
analyses.
Ab-extraction from mouse brains and Ab ELISA
The frozen brain halves of the intranasally treated animals were
homogenized according to the protocol published by Shankar et al
[46]. The resulting extracts TBS, TBS-Tx and GuHCl were stored
at 280uC until further processing.
The Ab1-40 and Ab1-42 –levels in the resulting extracts were
measured with the hAmyloid b40 and b42 ELISA Kits (The
Genetics Company, Schlieren, Switzerland). ELISA was per-
formed according to the manufacturer’s protocol. Briefly, the
standard and samples (in corresponding dilutions) were incubated
together with an antibody conjugate o/n at 4uC on a plate pre-
coated with antibody. After washing, the plates were incubated
with enzyme conjugate for 30 min at RT. After incubation with
the enzyme substrate for 25 to 30 min, the reaction was stopped
by adding 1M H2SO4 and the plates were measured at 450 nm
and 620 nm on a Tecan Sunrise plate reader (Tecan).
Western Blot analysis
Brain extracts were analyzed by Western Blotting. Equal
amounts of protein were separated on a 4–12% Bis-Tris gel
(Invitrogen), transferred to a nitrocellulose membrane and blocked
in TBS containing 5% skim milk and 0.1% Tween 20. Primary
antibodies anti-His, 1:500 (Qiagen) and 6E10, 1:1000 (Covance)
were incubated overnight at 4uC, and the corresponding
secondary antibodies were incubated for 1 h at room temperature.
SuperSignal West Dura (Pierce) was used for the detection of
chemiluminescence. Signals were detected using the ImageQuant
LAS4000 (GE Healthcare) and densitometric analysis was
performed using the GeneTools software (Syngene, Frederick,
MD) using the brain extracts from the vehicle cohort as reference
for normalization.
Statistical analysis
Data were expressed as means 6 SEM. Statistical analysis was
performed by ANOVA and Bonferronis or Fishers PLSD Post-hoc
tests using the GraphPad Prism 5 (GraphPad Software Inc., La
Jolla, CA) and the StatView (SAS Institute Inc., Cary, NC)
Software. A value of p,0.05 was considered statistically
significant.
Results
Structure and binding properties of 22C4 scFv
The single-chain variable Fragment (scFv) antibody 22C4 scFv
was generated by grafting the CDRs of the mouse monoclonal IgG
22C4 into a human scFv framework. The resulting antibody
fragment (3D structure see Figure S1A) had a size of 26517 Da as
determined by electrospray mass spectroscopy, was stable up to a
temperature of 62.8uC as measured by FT-IR (Figure S1B) and
retained the specificity of the full IgG for the amino acid residues
32–42 at the C-terminal end of the monomeric species of the
amyloid-beta peptide (Fig. 1A). The EC50 of 22C4 scFv was
calculated to be 280 nM and 130 nM for 22C4 IgG. However,
there was no difference between synthetic and recombinant Ab1-42
as epitope on plate (data not shown). As a more quantitative
affinity assessment of the antibody-Ab-complex, the KD values of
22C4 scFv and 22C4 IgG were determined by BioLayer
Interferometry (Octet System), in which the interference pattern
of white light is measured. From the shift in the interference
pattern the KD value for 22C4 scFv was calculated to be 54 nM
and 12 nM for 22C4 IgG (Fig. 1C). This difference in the
apparent surface affinities is most probably due to the bivalent
binding mode of the IgG as compared to the monovalency of the
scFv.
To further characterize the specificity of 22C4 scFv binding to
Ab1-42 a competition ELISA and an analytical SEC were
performed. For the competition ELISA 10 nM of 22C4 scFv
were competed with increasing amounts of recombinant Ab1-42.
Accordingly, the signal of scFv bound to Ab1-42 on the plate
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showed a dose-dependent decrease indicating the specificity of
22C4 scFv for Ab1-42 (Fig. 1B). This was further substantiated as
the competition with scrambled Ab1-42 did not show any non-
specific binding to 22C4 scFv (data not shown). During
competition, the binding equilibrium of the scFv to its target
peptide was not disturbed as the control plate showed 95% signal
as compared to the assay plate. For the analytical SEC, FITC-
labeled Ab1-42 and either 22C4 scFv or the non-specific Fw2.3
were pre-incubated at equimolar concentrations (1 mM). The gel
filtration revealed that 22C4 scFv and Ab1-42 eluted together
(Fig. 1D) whereas the non-specific control scFv Fw 2.3 and Ab1-42
eluted at different volumes (Fig. 1E). The pre-incubation was
repeated under different conditions varying incubation time and
temperature, which both had no influence on the result (data not
shown). FITC-Ab1-42 and 22C4 scFv eluted together even when
both were combined directly before injection into the column,
indicating that binding of Ab1-42 by 22C4 scFv was a fast and
nearly complete reaction. These results suggest that the scFv 22C4
Figure 1. Binding properties of 22C4 scFv. A Binding activity of 22C4 scFv was determined by ELISA on an Ab1-42-coated plate and compared to
the corresponding full IgG 22C4. EC50 of 22C4 scFv was calculated to be 2.8*1027 M and 1.3*1027 M for 22C4 IgG. There was no difference between
synthetic and recombinant Ab1-42 as epitope on plate. B The specificity of 22C4 scFv to Ab1-42 was determined by competition ELISA on Ab1-42 -
coated plate. 10 nM 22C4 scFv were competed with increasing amounts of recombinant Ab1-42. Competition with scrambled Ab1-42 did not show any
non-specific binding to 22C4 scFv (Data not shown). C Determination of the KD value by BioLayer Interferometry (Octet System). Both the scFv and
the IgG were measured at 50 nM. 22C4 scFv was additionally measured at 75 and 125 nM (data not shown). The KD value for 22C4 scFv was
calculated to be 2.7*1028 M and 1.2*1028 M for 22C4 IgG. The shift of the curves between 22C4 IgG and scFv does not correlate with their affinity to
Ab1-42, but with the size of the molecule. D and E SEC analysis of FITC- Ab1-42 (black, 495 nm) pre-incubated with either 22C4 scFv (red, 215 nm) or
the non-specific scFv Fw 2.3 (red). 22C4 scFv and Ab1-42 eluted together in a single peak (D) whereas Fw 2.3 and Ab1-42 eluted in 2 different peaks (E).
doi:10.1371/journal.pone.0018296.g001
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scFv is a small and highly specific antibody fragment that retained
most of the binding properties of the full IgG 22C4 it was derived
from. It exhibited good binding characteristics that are compara-
ble to those of 22C4 IgG.
22C4 scFv binds to amyloid plaques both in vitro and in
vivo
To test whether 22C4 scFv bound to Ab1-42 not only in ELISA
assays but also retained its activity on ex vivo tissue samples, brains
from different AD mouse models and human AD brains were
incubated with either 22C4 scFv (Fig. 2 A, C, E, G, I) or 22C4 IgG
(Fig. 2 B, D, F, H, J). Both the scFv and the full IgG recognized
amyloid plaques and CAA with comparable quality, but there
were some differences between the tested tissues depending on the
tissue origin. Amyloid deposits were best detected in APPswe/PS1
and APPswe/PS1dE9 brains with the least background staining
(Fig. 2A and B, E and F). Deposits in human AD brains were
detected with comparable sensitivity but with a somewhat stronger
background staining (Fig. 2 G and H). Finally, both 22C4 scFv and
22C4 IgG were tested on sections from ArcAb mice, which yielded
the weakest staining of amyloid deposits with the strongest
background staining (Fig. 2 C and D). Therefore, we decided to
perform all following experiments in APPswe/PS1dE9 mice.
To test whether 22C4 IgG and 22C4 scFv also bound to
amyloid plaques and CAA in vivo, brain sections from animals that
were treated intranasally for 14 weeks with either 22C4 scFv
(30 mg twice a week), 22C4 IgG (20 mg once a week) or PBS (once
a week) were stained with an anti-5xHis antibody or an anti-mouse
Cy3 antibody to detect 22C4 scFv and 22C4 IgG, respectively
(Fig 2 K to N). The scFv clearly labeled plaques (Fig. 2 K), whereas
the full IgG could not be detected in the brains of treated animals
(Fig. 2 M). Control animals treated with PBS that were stained
equally showed a weak background staining for both treatment
groups (Fig. 2 L and N), but the staining for 22C4 scFv was much
stronger as compared to the negative control. These suggested that
scFv 22C4 had readily entered the brain and labeled amyloid
plaques in vivo.
22C4 scFv inhibits both Ab1-42 aggregation and
neurotoxicity in vitro but does not bind to full-length APP
Antibodies and antibody fragments directed against the amyloid
beta-peptide could have the undesirable side effect to also bind to
full-length APP, thereby possibly interfering with APP function
and processing. To exclude this possibility we performed an in vitro
binding assay in which HEK293T cells transfected with an APP-
Citrine expressing construct were incubated with either antibody
6E10 as a positive control (Fig. 3 A), 22C4 IgG (Fig. 3 B), 22C4
scFv (Fig. 3 C) or corresponding non-specific antibodies for 30 min
on ice (data not shown). After fixation fluorescence staining
revealed that neither 22C4 scFv nor 22C4 IgG nor the non-
specific control antibodies had bound to full-length APP, whereas
6E10 showed the expected co-localization (Fig. 3A). This finding
confirmed that neither the scFv nor the full IgG specific for the C-
terminus of Ab1-42 bound to full-length APP suggesting that
treatment with 22C4 scFv or 22C4 IgG was unlikely to be
associated with an altered processing or trafficking of the APP
molecule as a result of antibody binding; moreover, the finding
excluded the possibility that full-length APP might act as a sink for
the applied antibody.
We next tested whether 22C4 scFv was able to inhibit Ab1-42–
mediated neurotoxicity. Primary cortical neurons from rat
embryos (E18) were incubated with 5 mM recombinant Ab1-42,
0.5 mM 22C4 scFv or both for 48 h (Fig. 3 D), and neurons treated
with both Ab1-42 and 22C4 scFv exhibited significantly less cell
death (*** p,0.005) when compared to cells treated with Ab1-42
alone, indicating that 22C4 scFv indeed inhibited Ab1-42-mediated
neurotoxicity in vitro. This result was further supported by
immunostaining of cultured rat cortical neurons which had been
treated with 5 mM Ab1-42, 0.5 mM 22C4 scFv or both for 24 h.
The staining revealed that neurons in control wells and wells that
had been treated with Ab1-42 and 22C4 scFv showed more intact
neuronal morphology with longer processes and less apoptotic
neurons than neurons that were treated with 5 mM Ab1-42 alone
(Fig. 3 E to H). Immunostaining with an anti-Ab1-42 antibody
revealed that neurons were surrounded by Ab1-42 aggregates. Ab1-42
aggregates could also be detected in close association with
significantly shortened neuritic processes (Figure S2).
The ability of 22C4 scFv to inhibit Ab1-42 aggregation was
assessed in an aggregation inhibition assay. Monomeric Ab1-42
(2.5 mM) was incubated either alone or with the addition of 22C4
scFv at 2.5 mM, 1.25 mM or 0.25 mM (Fig. 3 I). The Thioflavin T
fluorescence, which shows fluorescence at l=480 nm in the
presence of b-sheet structures, was measured over a time of
180 min. The fluorescence did not increase when Ab1-42 was co-
incubated with equimolar concentrations of 22C4 scFv when
compared to the peptide alone, indicating that the scFv inhibited
Ab1-42 aggregation. When the scFv was added to the assay at
substoichiometric concentrations it reduced fibril formation rather
than completely inhibiting Ab1-42 aggregation. Notably, 22C4
scFv only inhibited aggregation completely when added to Ab1-42
at the beginning of the assay. When added after the onset of
aggregation, 22C4 scFv did not inhibit aggregation but rather
delayed progression (Figure S3A). This observation further
supported the idea that 22C4 scFv predominantly bound to linear
(monomeric) state of Ab1-42, and that it inhibited its aggregation
via interference with the initial seed formation.
22C4 scFv lowers plaque number and reduces insoluble
Ab levels in the brains of intranasally treated APP
transgenic mice
After determination of the binding characteristics and in vitro
properties of 22C4 scFv, we further analyzed the scFv’s in vivo
efficacy. APPswe/PS1dE9 mice were treated intranasally for 14
weeks with either 22C4 scFv, 22C4 IgG or PBS, before significant
amyloid deposition had occurred. After the final application, all
brains were analyzed immunohistochemically and biochemically.
The DAB staining of brain sections with 6E10 antibody showed a
significant difference in plaque density between the treatment
groups (Fig. 4 A to C). The quantitative analysis of the plaque
number revealed that animals treated with 22C4 scFv had a
significantly lower plaque number when compared to PBS treated
animals (Fig 4 D; * p,0.05). However, there was no difference in
plaque size between the treatment groups (Fig. 4 E). Additionally,
Thioflavin S staining was performed to determine the number of
CAA-positive vessels in the treated mice. This analysis showed a
significantly decreased number of CAA-positive vessels in 22C4
scFv (*** p,0.005) and 22C4 IgG (* p,0.05) treated animals
when compared to PBS treated controls (Fig. 4 F).
For further analysis hemi brains of all treated animals were
homogenized and extraction of Ab was performed. Ab1-40 (Fig. 4
G to I) and Ab1-42 levels (Fig. 4 J to L) in different fractions was
then determined by ELISA. In the TBS fraction, soluble Ab1-40
was significantly increased in the 22C4 scFv treated animals
compared to PBS treated animals, whereas Ab1-42 was slightly,
though not significantly, increased. Neither Ab1-40 nor Ab1-42
levels were significantly different among the treatment groups in
the membrane-bound TBS Triton fraction; in the ‘‘insoluble’’
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GuHCl-fraction, however, levels of both Ab1-40 and Ab1-42 were
significantly decreased. However, Ab1-40 was only slightly reduced
whereas Ab1-42 was significantly decreased in the 22C4 scFv
treated animals as compared to the PBS treated group (* p,0.05).
Analysis of serum Ab1-40 and Ab1-42 levels revealed no statistically
significant differences among the treatment groups (Figure S4).
Moreover, Western blot analysis of TBS soluble extracts showed
similar distributions of oligomeric Ab species among the different
treatment groups (Figure S5). The latter finding indicated that the
increase of Ab1-40 in the TBS fraction was not associated with an
concomitant increase in potentially neurotoxic Ab oligomers.
In summary, when administered intranasally, 22C4 scFv lowered
the number of amyloid plaques and CAA-positive vessels in
transgenic mice with brain amyloidosis. These results were further
substantiated by the fact that the levels of Ab1-40 and Ab1-42
were significantly decreased in the insoluble fraction but increased in
the soluble fraction of 22C4 scFv treated animals, suggesting a
redistribution of brain Ab from the insoluble fraction to the soluble
peptide pool, which was not accompanied by an increase of serum
Ab levels or increased amounts of oligomeric Ab species.
Interestingly, all treatment effects were more pronounced in
animals treated with scFv as compared to those treated with the
corresponding full IgG.
Discussion
Immunotherapeutic strategies for clearing Ab from the brain
[47] include active immunization by either systemic Ab injection
[5,48,49] or by nasal administration of the whole Ab peptide
[50,51] or short Ab immunogens [52], as well as passive
immunization strategies with monoclonal antibodies [6,15,16,
53,54,55,56,57] or antibody fragments [29,30]. Ab immunother-
apy can decrease both cerebral amyloid burden and brain levels of
Ab, attenuate neuritic dystrophy, astrogliosis, and behavioral
deficits, restore blood-brain barrier integrity [54] and prevent
synaptic degeneration [58].
In this study we generated a humanized scFv against the C-
terminus of Ab. It was derived from the full IgG 22C4 [56,32] by
grafting the CDRs into a human scFv framework. The resulting
scFv antibody 22C4 scFv retained most of the binding properties
of the full IgG 22C4 it had been derived from. The scFv exhibited
good binding characteristics with high affinity and specificity to
Ab. 22C4 scFv was identified to bind to both synthetic and
recombinant Ab in in vitro assays as well as to natural Ab in
transgenic mouse and human tissues. Moreover, we showed that
22C4 scFv labeled Ab deposits in vivo.
22C4 scFv potently inhibited Ab aggregation and Ab-mediated
neurotoxicity in vitro, presumably by binding to Ab monomers
thereby blocking their assembly to larger and potentially
Figure 2. 22C4 scFv binds to plaques both ex and in vivo. A to J
Both the scFv and the corresponding full IgG were tested for their
ability to label plaques in brains of different mouse models of AD and
on human AD brains. Paraffin sections were stained with 22C4 scFv (A,
C, E, G, I) and detected with an anti-His and an anti-rabbit Cy3 antibody
or stained with 22C4 IgG (B, D, F, H, J), which was detected directly with
an anti-mouse Cy3 antibody. APPswe/PS1 (A and B); ArcAbeta (C and D),
APPswe/PS1dE9 (E an F), human AD (G and H), WT (I and J). Both the
scFv and the full IgG recognized plaques in all tested tissues in
comparable quality (Scale Bar: 200 mm). K to N After 12 weeks of
intranasal application of 22C4 scFv (K) and 22C4 (M) in APPswe/PS1dE9
mice only the scFv was detectable in treated animals indicating that
22C4 IgG did not reach the brain in detectable amounts. The control
animals were treated with PBS and stained for 22C4 scFv (L) and 22C4
IgG (N) accordingly (Scale Bar: 200 mm).
doi:10.1371/journal.pone.0018296.g002
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neurotoxic oligomeric aggregates. Another possibility might be
that this effect could be related to a sterical hindrance of Ab to
form aggregation seeds. Aggregation might be inhibited or
disturbed when the concentration of an interfering agent is
sufficient to modulate the formation of aggregation seeds as it is
the case for human serum albumin (HSA) [59]. According to this
theory, Rozga et al stated that the relative abundance of the low
affinity HSA in serum is responsible for the aggregation-inhibiting
effect on peripheral Ab. In contrast, a specific Ab-binding reagent
should be able to inhibit aggregation at equimolar concentrations
due to its higher affinity to Ab [24]. Indeed, we could show that
22C4 scFv reduced Ab aggregation even in substoichiometric
concentration and it did so to a greater extent than the non-
specific BSA (Figure S3B). Notably, 22C4 scFv only inhibited
aggregation completely when added to Ab1-42 at the beginning of
the assay. When added after the onset of aggregation, 22C4 scFv
could not inhibit aggregation but rather delayed aggregation
progression. This observation further supports the idea that 22C4
scFv predominantly binds monomeric Ab1-42, and that it can
inhibit its aggregation as long as aggregation seeds have not yet
formed. After the beginning of seed formation, aggregation can
rather be delayed than inhibited. This might also explain how
22C4 scFv reduced Ab-mediated neurotoxicity. After binding of
the scFv to Ab monomers, the formation of aggregation seeds and
Figure 3. 22C4 scFv inhibits Ab1-42 aggregation and neurotoxicity in vitro without binding to full length APP. A to C HEK293T cells
were transfected with an APP-Citrine (yellow) expressing construct. The cells were then incubated with either 6E10 (A), 22C4 scFv (B) or 22C4 IgG (C)
(red) for 30 min on ice, fixed and fluorescence stained. The staining revealed that only 6E10 bound to full length APP. Incubation with control
antibodies (Fw2.3, 2H6C2) showed similar staining compared to (B) and (C). Staining with secondary antibody did not show any staining (data not
shown) (Scale Bar: 10 mm)D to H Primary Cortical Neurons from Rat (DIV5) were incubated with 5 mM recombinant Ab1-42, 0.5 mM 22C4 scFv or both for
48 h. D Neurotoxicity analysis determined by Luminescence indicating cell death. Wells treated with Ab1-42 showed significantly more dead cells as
compared to control wells that were treated with H2O. The addition of 22C4 scFv significantly decreased cell death indicating that it inhibited Ab1-42
neurotoxicity (*** p,0.005). E to H After treatment the cells were fixed with PFA and stained with anti-Map2 (green) and anti-Cleaved Caspase 3 (red)
antibodies. Neurons in control wells (vehicle control E and 22C4 scFv G) and wells that were treated with Ab1-42 and 22C4 scFv (H) showed better
neuronal morphology with longer processes and less apoptotic neurons than neurons that were treated with 5 mM Ab1-42 alone (F) (Scale Bar: 50 mm). I
Monomeric recombinant Ab1-42 (2.5 mM) was incubated at 25uC and 500 mM NaCl either alone or with 2.5 mM, 1.25 mM or 0.25 mM of 22C4 scFv. The
Thioflavin T fluorescence of all four reactions was measured simultaneously every 3 min for 180 min. The addition of 22C4 scFv to the aggregation assay
showed a dose-dependent effect on Ab1-42 aggregation. Aggregation was delayed when using Ab1-42-scFv ratios of 10:1 and could almost be completely
prevented when using equimolar concentrations.
doi:10.1371/journal.pone.0018296.g003
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potentially toxic higher order species, such as oligomers and fibrils,
was inhibited [47].
In this study we report the novel finding that chronic intranasal
treatment of APPswe/PS1dE9 mice with 22C4 scFv and 22C4
IgG resulted in decreased Ab accumulation in the parenchyma
and vessels of the brain and accordingly also showed decreased Ab
levels in the insoluble fraction but increased levels in the soluble
fraction of brain extracts. Animals treated with 22C4 scFv
exhibited significantly less plaques in brain parenchyma, but there
was no statistical difference in plaque size among the treatment
groups. This might be due to the fact that the APP transgenic mice
used in this study typically develop only small dense core plaques
that do not grow significantly in size with disease progression [42].
As a result, the variation in plaque size is generally low in this
model which might explain why our treatment lowered plaque
numbers but did not significantly affect plaque size. The reduction
in Ab accumulation in brain parenchyma and brain vasculature
was accompanied by a redistribution of Ab from the insoluble to
the soluble peptide pool. However, this redistribution was not
accompanied by an increase in potentially neurotoxic Ab
oligomers as revealed by 6E10 Western Blotting (Figure S5).
Western blot analysis showed the presence of scFv in the brain
as early as 1 h after intranasal application (Figure S6), suggesting
rapid transport that is possibly compatible with the idea that 22C4
scFv enters the brain via perineural channels in the subarachnoid
space of the nasal cavity and binds to amyloid plaques. The uptake
of a molecule along the nasal pathway from nose to CNS is
thought to involve two general mechanisms. The first is
internalization of the molecule into the primary neurons of the
olfactory epithelium and intracellular transport along the axon to
the olfactory bulb and subsequent distribution in the brain tissue.
The axonal route of transport is slow and molecules reach the
CNS 24 h after application [36]. The second pathway, the
olfactory epithelial pathway, has been reported to be faster [36]. It
relies on a direct anatomic connection between the submucosa and
the subarachnoid extensions, the perineural space surrounding the
olfactory nerves, as they penetrate the cribiform plate [38]. It has
been shown in rats that even large molecular weight compounds
like nerve growth factor [60], insulin-like growth factor [33] and
interferon-beta [35] can be transported rapidly into the CNS and
distribute in the tissue in a time- and region-dependent manner.
Accordingly, our results support the idea that 22C4 scFv was
transported along the olfactory epithelial pathway, subsequently
distributed in the brain tissue and was eliminated via blood
[36,38,41]. After its entry and distribution in the CNS, there are
three possible mechanisms by which 22C4 scFv might have
exerted its effect on amyloid pathology: (i) by binding to monomers
it could have prevented the formation of aggregation seeds and
thus the accumulation of plaques, (ii) it interferes with plaque
growth by binding to accessible C-terminal ends of the amyloid
beta peptide or (iii) the binding of monomers might have reduced
the concentration of free monomers which then could have led to
the disintegration of fibrils in order to keep the equilibrium.
Soluble monomers or scFv-bound monomers would then be
subject to degradation or elimination from the brain by efflux
mechanisms along the blood-brain barrier [47]. The latter
‘‘peripheral sink’’ mechanism, however, appears to be less likely
responsible for the observed decrease in amyloid pathology in our
study since we did not observe significant increases in serum Ab
levels in the 22C4 IgG- and scFv-treated animals as compared to
the PBS-treated mice (Figure S4).
Most of the mechanisms proposed for the clearance of Ab from
the brain (for review see [47]) rely on the presence of
therapeutically relevant antibody concentrations in the CNS.
Antibody transport across the BBB into the brain thus is a critical
issue. Available data from several studies estimate that only 0.1%
to 1% of plasma antibodies enter the CNS [10,11,61]. Neverthe-
less, immunohistological analysis of brain tissue from participants
of the AN1792 study showed antibodies bound to b-amyloid
plaques [62]. In line with this study, we were also able to detect the
scFv 22C4 scFv bound to plaques in the brains of treated APPswe/
PS1dE9 mice. In the brain antibodies might be stabilized by
binding to high local concentrations of target epitopes in b-
amyloid plaques which possibly results in very slow apparent off-
rates for the antibody-Ab interaction. As a result, antibodies
accumulate around brain Ab deposits, and even small amounts of
antibodies may thus be therapeutically relevant or cause
therapeutically relevant antibody concentrations over time [1].
In order to increase the antibody concentration in the brain, we
chose the intranasal route of delivery which circumvents the BBB
and leads to a fast time- and region- dependent distribution of
applied molecules in the brain [36,38]. Studies using dextran [40]
or NGF [63] in rats showed a strong dependence of the levels and
the distribution of the applied biologics in brain parenchyma on
molecular weight. These findings might also explain our
observation why all our experimental treatment effects appeared
to be more pronounced in mice treated with the smaller scFv as
compared to the full IgG. It is possible that the full IgG either
entered the brain in smaller quantities or that its distribution was
strongly reduced due to its larger molecule size as compared to the
scFv. Most studies that had evaluated intranasal application as
route of delivery to the brain were performed in the rat model
which most likely overestimates the degree of transport due to the
relatively larger surface of the olfactory epithelium and relatively
bigger olfactory bulbs of rats in comparison with humans [38,39].
Some studies performed in humans, however, confirmed the
existence of a direct pathway from the nose to the brain [38]. Born
et al. [39] demonstrated that the intranasal delivery of melano-
cortin, vasopressin and insulin resulted in increased levels of these
peptides in the CSF within 30 minutes, without increasing their
Figure 4. 22C4 scFv reduced amyloid plaque number and influenced the amount of Ab1-40 and Ab1-42 in brains of treated animals.
To determine the in vivo efficacy of 22C4 scFv APPswe/PS1dE9 mice were treated intranasally for 14 weeks with either 22C4 scFv, 22C4 IgG or PBS.
After the final application animals were euthanized and brain sections were DAB stained with 6E10. A to C Representative pictures of PBS (A), 22C4
IgG (B) and 22C4 scFv (C) treated animals (Scale Bar: 1 mm). D and E Evaluation of 6E10 staining with Image J. The plaque number (D) was
significantly reduced in 22C4 scFv and 22C4 IgG treated animals as compared to PBS treated animals, however, there was no difference in plaque size
(E) between the treatment groups (* p,0.05). F Determination of CAA-positive vessels by Thioflavin S staining. The number of vessels with CAA was
significantly decreased in mice treated with 22C4 IgG (* p,0.05) and 22C4 scFv (*** p,0.005) when compared to animals that had received PBS as a
control. G to I Determination of Ab1-40 and J to L Ab1-42 amount in brain homogenates from intranasally treated APPswe/PS1dE9 mice by ELISA. In
the TBS-fraction (G and J) the soluble Ab1-40 was significantly increased in 22C4 scFv treated animals as compared to PBS treated animals, Ab1-42 was
slightly but not significantly increased in the 22C4 scFv treated group. Neither Ab1-40 nor Ab1-42 was significantly changed between the treatment
groups in the membrane-bound TBS-Triton fraction (H and K). Both, the insoluble Ab1-40 and Ab1-42 in the GuHCl-fraction (I and L) were decreased.
However, Ab1-40 was only slightly reduced but Ab1-42 was significantly decreased in the 22C4 scFv treated animals as compared to the PBS treated
group (* p,0.05). Overall, we detected higher amounts of Ab1-42 than Ab1-40, which is in contrast to AD patients but correlates well with data
published for the APPswe/PS1dE9 mouse model [42].
doi:10.1371/journal.pone.0018296.g004
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levels in the bloodstream. Several studies also measured the
pharmacological effects of intranasally delivered molecules,
thereby strengthening the possibility of a direct and efficacious
nose-to-brain transport also in humans [38].
Studies in transgenic mice indicated the possibility that antibody
treatment leads to microhemorrhages associated with pre-existing
CAA [15,16]. This might be related to interactions of anti-Ab
antibodies with the vascular amyloid which causes local breaches
of the BBB due to degenerated smooth muscle and endothelial
cells [4,17]. Antibody-mediated microhemorrhages can also be
related to Fc effector functions since de-glycosylated IgG without
effector functions show a significantly reduced risk to induce
microhemorrhages [16,54]. This might also be true for scFv since
these antibody fragments miss the Fc effector domain, and in
agreement with this, we did not detect significantly increased
microhemorrhages in 22C4 scFv treated mice, when compared to
PBS-treated animals (Figure S7). Another concern is that CAA can
be increased due to antibody-mediated clearance of Ab from the
brain parenchyma and subsequent transport of Ab to the
vasculature and accumulation at the blood vessel walls [54,62].
On the other hand, it was shown that anti-Ab antibodies can also
reduce vascular amyloid without increasing the incidence of
microhemorrhages [64,65]. It is possible that the propensity of an
antibody to increase CAA is epitope-dependent [17]. The degree
of treatment-related effects such as microhemorrhages might vary
depending on the severity of baseline CAA pathology [61].
Furthermore, it was shown that an increased incidence of
microhemorrhages in an immunization study could be controlled
by lowering the antibody dosage [65]. Our results also
demonstrated that the 22C4 scFv reduced CAA in transgenic
mice without increasing microhemorrhages, which might be
attributable to the route of delivery. As previously discussed
Thorne et al. [33] states that one mechanism of intranasal delivery
of protein therapeutics to the brain is via perivascular channels,
which would put the scFv in direct contact with cerebrovascular
Ab. This is further supported by the fact that high levels of
interferon b-1b [66] and hypocretin-1 [67] were detected in blood
vessel walls after intranasal administration.
In this study we report for the first time that chronic intranasal
treatment of transgenic mice before the onset of Ab deposition
with 22C4 scFv resulted in decreased Ab accumulation in the
parenchyma and vessels of the brain and accordingly also showed
decreased Ab levels in the insoluble fraction but increased levels in
the soluble fraction. Our findings suggest that the scFv 22C4 may
be a useful alternative to full IgG molecules for reducing brain Ab
without triggering Fc-mediated effector functions and, possibly,
microhemorrhages. Furthermore, these findings broaden the
therapeutic potential of anti-Ab immunotherapy to the removal
of beta-amyloid from CAA lesion. Finally, this study further
supports intranasal delivery of protein therapeutics for the
treatment of CNS disorders, which has previously been shown
to be efficacious in non-human primates [68] and humans [69,70].
Supporting Information
Figure S1 A 3D-model of 22C4 scFv generated using the
SWISS-MODEL Repository which is a database of annotated
three-dimensional comparative protein structure models generated
by the fully automated homology-modeling pipeline SWISS-
MODEL. The repository was developed at the BioCenter Basel
(Swiss Institute of Bioinformatics). Blue: linker; Red: CDRs;
Green: site where 22C4 scFv is hydrolyzed. B Measurements of
the FT-IR spectrum with increasing temperature from 25uC to
95uC to determine thermal stability. The melting temperature of
22C4 scFv (50% unfolding of the protein) was determined to be at
62.8uC.
(TIF)
Figure S2 Immunostainings of primary rat cortical neurons
(DIV5) which had been incubated with 5 mM recombinant Ab42
before they were fixed with paraformaldehyde and stained with
anti-Map2 (green) and anti-Ab1-42 (red) antibodies. Neurons show
damaged neuronal morphology, swollen somata and shortened
processes in close association with Ab42 aggregates (Scale Bar:
50 mm).
(TIF)
Figure S3 A 2.5 mM monomeric recombinant Ab42 was
incubated in 500 mM NaCl at 25uC alone or with equimolar
concentrations of 22C4 scFv which was added to the stirred assay
either when ThioT fluorescence reached half-maximal or maximal
intensity. Complete inhibition of Ab42 aggregation by 22C4 scFv
was only achieved when 22C4 scFv was added to Ab42 at the
beginning of the assay. When added after onset of aggregation,
22C4 scFv did not effectively inhibit Ab42 aggregation but rather
delayed the progression of the aggregation process. B Monomeric
recombinant Ab42 was incubated in 500 mM NaCl at 25uC alone
or with either equimolar or half-equimolar concentrations of BSA.
When Ab42 was incubated with BSA that binds to Ab42
unspecifically, only a slight reduction in fibril formation was
detectable even with equimolar concentrations of BSA.
(TIF)
Figure S4 Serum Ab1-40 (A) und Ab1-42 (B) levels in the
intranasally treated APPswe/PS1dE9 mice as determined by
ELISA. Serum was taken at the beginning of the treatment period
and after the application of the final dose of the biologic. Ab levels
at the beginning of the treatment were subtracted from the levels
at the end of the treatment period. No significant differences in
serum Ab1-40 and Ab1-42 levels could be detected among the
different treatment groups, although 22C4 IgG and 22C4 scFv
treated mice tended to show lower Ab1-40 levels at the end of the
intranasal treatment.
(TIF)
Figure S5 A Exemplary Western Blot of TBS brain extracts
from intranasally treated APPswe/PS1dE9 mice. Bands detected
with 6E10 antibody had apparent molecular weight of 4 kDa
(corresponds to Ab monomer), 14 kDa (trimer), 22 kDa (hexamer)
and 52 kDa (probably corresponds to dodecamer). B Quantifica-
tion of bands revealed no significant differences in oligomer
distribution between treatment groups.
(TIF)
Figure S6 Western blot analysis of brain extracts from
intranasally treated animals that were sacrificed 1 h after
treatment with 200 mg 22C4 scFv. For the detection of the scFv,
an anti-His primary antibody (Cell Signaling, 1:1000) was used. It
recognizes a 27 kDa band, which corresponds to the size of the
scFv, and which could be detected in cortical (CX) and
hippocampal (HPC) extracts. No significant amounts of scFv were
detectable in the cerebellum (CBL) and the olfactory bulb (OB)
after 1 h. 6 h after the treatment, scFv was not detectable by
Western Blotting in any region (data not shown).
(TIF)
Figure S7 Perl’s Prussian blue histological stainings for micro-
hemorrhages (counterstained with Nuclear Fast Red) of paraffin
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sections from intranasally treated animals. Microhemorrhages
were slightly but not significantly increased in 22C4 scFv treated
animals when compared to control animals. Microhemorrhages
were most abundant in the olfactory bulb. Representative pictures
of PBS (A), 22C4 IgG (B) and 22C4 scFv treated animals (C) after
14 weeks of treatment (Scale bar: 200 mm). D Quantitative
analysis of Perl’s Prussian blue histological stainings revealed that
microhemorrhages were slightly but not significantly increased in
22C4 scFv treated animals when compared to control animals.
(TIF)
Acknowledgments
We would like to thank ESBA Tech (Schlieren, Switzerland) for production
and purification of 22C4 scFv and also Nadine Lucke (Neurimmune
Therapeutics AG) for excellent technical support.
Author Contributions
Conceived and designed the experiments: SC RMN. Performed the
experiments: SC MH LK. Analyzed the data: SC MH. Contributed
reagents/materials/analysis tools: LK RMN. Wrote the paper: SC MH
LK. Reviewed manuscript: MH LK RMN.
References
1. Nitsch RM, Hock C (2008) Targeting beta-amyloid pathology in Alzheimer’s
disease with Abeta immunotherapy. Neurotherapeutics 5(3): 415–420.
2. Weiner HL, Frenkel D (2006) Immunology and immunotherapy of Alzheimer’s
disease. Nat Rev Immunol 6(5): 404–416.
3. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer’s disease:
progress and problems on the road to therapeutics. Science 297(5580): 353–356.
4. Kumar-Singh S (2008) Cerebral amyloid angiopathy: pathogenetic mechanisms
and link to dense amyloid plaques. Genes Brain Behav 7(Suppl 1): 67–82.
5. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, et al. (1999)
Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in
the PDAPP mouse. Nature 400(6740): 173–177.
6. Bard F, Cannon C, Barbour R, Burke RL, Games D, et al. (2000) Peripherally
administered antibodies against amyloid beta-peptide enter the central nervous
system and reduce pathology in a mouse model of Alzheimer disease. Nat Med
6(8): 916–919.
7. Bayer AJ, Bullock R, Jones RW, Wilkinson D, et al. (2005) Evaluation of the
safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD.
Neurology 64(1): 94–101.
8. Orgogozo JM, Gilman S, Dartigues JF, Laurent M, Puel M, et al. (2003)
Subacute meningoencephalitis in a subset of patients with AD after Abeta42
immunization. Neurology 61(1): 46–54.
9. Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, et al. (2005) Clinical
effects of Abeta immunization (AN1792) in patients with AD in an interrupted
trial. Neurology 64(9): 1553–1562.
10. Hock C, Konietzko U, Papassotiropoulos A, Wollmer A, Streffer JR, et al. (2002)
Generation of antibodies specific for beta-amyloid by vaccination of patients
with Alzheimer disease. Nat Med 8(11): 1270–1275.
11. Hock C, Konietzko U, Streffer JR, Tracy J, Signorell A, et al. (2003) Antibodies
against beta-amyloid slow cognitive decline in Alzheimer’s disease. Neuron
38(4): 547–554.
12. Town T, Tan J, Flavell RA, Mullan M (2005) T-cells in Alzheimer’s disease.
Neuromolecular Med 7(3): 255–64.
13. Town T (2009) Alternative Abeta immunotherapy approaches for Alzheimer’s
disease. CNS Neurol Disord Drug Targets 8(2): 114–27.
14. Fu HJ, Liu B, Frost JL, Lemere CA (2010) Amyloid-beta immunotherapy for
Alzheimer’s disease. CNS Neurol Disord Drug Targets 9(2): 197–206.
15. Pfeifer M, Boncristiano S, Bondolfi L, Stalder A, Deller T, et al. (2002)
Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science
298(5597): 1379.
16. Wilcock DM, Rojiani A, Rosenthal A, Levkowitz G, Subbarao S, et al. (2004)
Passive amyloid immunotherapy clears amyloid and transiently activates
microglia in a transgenic mouse model of amyloid deposition. J Neurosci
24(27): 6144–6151.
17. Racke MM, Boone LI, Hepburn DL, Parsadainian M, Bryan MT, et al. (2005)
Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in
amyloid precursor protein transgenic mice by immunotherapy is dependent on
antibody recognition of deposited forms of amyloid beta. J Neurosci 25(3):
629–636.
18. Wilcock DM, Alamed J, Gottschall PE, Grimm J, Rosenthal A, et al. (2006)
Deglycosylated anti-amyloid-beta antibodies eliminate cognitive deficits and
reduce parenchymal amyloid with minimal vascular consequences in aged
amyloid precursor protein transgenic mice. J Neurosci 26(20): 5340–5346.
19. Bacskai BJ, Kajdasz ST, McLellan ME, Games D, Seubert P, et al. (2002) Non-
Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by
immunotherapy. J Neurosci 22(18): 7873–7878.
20. Auf der Maur A, Escher D, Barberis A (2001) Antigen-independent selection of
stable intracellular single-chain antibodies. FEBS Lett 508(3): 407–412.
21. Burmester J, Spinelli S, Pugliese L, Krebber A, Honegger A, et al. (2001)
Selection, characterization and x-ray structure of anti-ampicillin single-chain Fv
fragments from phage-displayed murine antibody libraries. J Mol Biol 309(3):
671–685.
22. Holliger P, Hudson PJ (2005) Engineered antibody fragments and the rise of
single domains. Nat Biotechnol 23(9): 1126–1136.
23. Auf der Maur A, Zahnd C, Fischer F, Spinelli S, Honegger A, et al. (2002)
Direct in vivo screening of intrabody libraries constructed on a highly stable
single-chain framework. J Biol Chem 277(47): 45075–45085.
24. Yue S, Li Y, Wang X, Bai H, Xia J, et al. (2008) The toxicity of beta-amyloid is
attenuated by interaction with its specific human scFv E3 in vitro. Life Sci 82(25-
26): 1249–1255.
25. Frenkel D, Solomon B, Benhar I (2000) Modulation of Alzheimer’s beta-amyloid
neurotoxicity by site-directed single-chain antibody. J Neuroimmunol 106(1-2):
23–31.
26. Liu R, Yuan B, Emadi S, Zameer A, Schulz P, et al. (2004) Single chain variable
fragments against beta-amyloid (Abeta) can inhibit Abeta aggregation and
prevent abeta-induced neurotoxicity. Biochemistry 43(22): 6959–6967.
27. Solorzano-Vargas RS, Vasilevko V, Acero G, Ugen KE, Martinez R, et al.
(2008) Epitope mapping and neuroprotective properties of a human single chain
FV antibody that binds an internal epitope of amyloid-beta 1-42. Mol Immunol
45(4): 881–886.
28. Zameer A, Schulz P, Wang MS, Sierks MR (2006) Single chain Fv antibodies
against the 25-35 Abeta fragment inhibit aggregation and toxicity of Abeta42.
Biochemistry 45(38): 11532–11539.
29. Fukuchi K, Accavitti-Loper MA, Kim HD, Tahara K, Cao Y, et al. (2006)
Amelioration of amyloid load by anti-Abeta single-chain antibody in Alzheimer
mouse model. Biochem Biophys Res Commun 344(1): 79–86.
30. Levites Y, Jansen K, Smithson LA, Dakin R, Holloway VM, et al. (2006)
Intracranial adeno-associated virus-mediated delivery of anti-pan amyloid beta,
amyloid beta40, and amyloid beta42 single-chain variable fragments attenuates
plaque pathology in amyloid precursor protein mice. J Neurosci 26(46):
11923–11928.
31. Mohajeri MH, Gaugler MN, Martinez J, Tracy J, Li H, et al. (2004) Assessment
of the bioactivity of antibodies against beta-amyloid peptide in vitro and in vivo.
Neurodegener Dis 1(4-5): 160–167.
32. Gaugler MN, Tracy J, Kuhnle K, Crameri A, Nitsch RM, et al. (2005)
Modulation of Alzheimer’s pathology by cerebro-ventricular grafting of
hybridoma cells expressing antibodies against Abeta in vivo. FEBS Lett
579(3): 753–756.
33. Thorne RG, Pronk GJ, Padmanabhan V, Frey II WH (2004) Delivery of insulin-
like growth factor-I to the rat brain and spinal cord along olfactory and
trigeminal pathways following intranasal administration. Neuroscience 127(2):
481–496.
34. De Rosa R, Garcia AA, Braschi C, Capsoni S, Maffei L, et al. (2005) Intranasal
administration of nerve growth factor (NGF) rescues recognition memory deficits
in AD11 anti-NGF transgenic mice. Proc Natl Acad Sci USA 102(10):
3811–3816.
35. Ross TM, Martinez PM, Renner JC, Thorne RG, Hanson LR, et al. (2004)
Intranasal administration of interferon beta bypasses the blood-brain barrier to
target the central nervous system and cervical lymph nodes: a non-invasive
treatment strategy for multiple sclerosis. J Neuroimmunol 151(1-2): 66–77.
36. Graff CL, Pollack GM (2005) Nasal drug administration: potential for targeted
central nervous system delivery. J Pharm Sci 94(6): 1187–1195.
37. Lawrence D (2002) Intranasal delivery could be used to administer drugs directly
to the brain. Lancet 359(9318): 1674.
38. Illum L (2004) Is nose-to-brain transport of drugs in man a reality? J Pharm
Pharmacol 56(1): 3–17.
39. Born J, Lange T, Kern W, McGregor GP, Bickel U, et al. (2002) Sniffing
neuropeptides: a transnasal approach to the human brain. Nat Neurosci 5(6):
514–516.
40. Sakane T, Akizuki M, Taki Y, Yamashita S, Sezaki H, et al. (1995) Direct drug
transport from the rat nasal cavity to the cerebrospinal fluid: the relation to the
molecular weight of drugs. J Pharm Pharmacol 47(5): 379–381.
41. Graff CL, Zhao R, Pollack GM (2005) Pharmacokinetics of substrate uptake and
distribution in murine brain after nasal instillation. Pharm Res 22(2): 235–244.
42. Garcia-Alloza M, Robbins EM, Zhang-Nunes SX, Purcell SM, Betensky RA,
et al. (2006) Characterizeation of amyloid deposition in the APPswe/PS1dE9
mouse model of Alzheimer disase. Neurobiol Dis 24: 516–524.
43. Holcomb L, Gordon MN, McGowan E, Yu X, Benkovic S, et al. (1998)
Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant
amyloid precursor protein and presenilin 1 transgenes. Nature 4(1): 97–100.
44. Knobloch M, Konietzko U, Krebs DC, Nitsch RM (2007) Intracellular Ab and
cognitive deficits precede b-amyloid deposition in transgenic arcAb mice.
Neurobiol Aging 28: 1297–1306.
Intranasal Treatment with Anti-Ab42 scFv
PLoS ONE | www.plosone.org 12 April 2011 | Volume 6 | Issue 4 | e18296
45. Hanson LR (2004) Intranasal administration of Hypocretin 1 (Orexin A)
bypasses the blood-brain barrier and targets the brain: A new strategy for the
Treatment of Narcolepsy. Drug Delivery Technology 4(4): 66–71.
46. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, et al. (2008)
Amyloid-beta protein dimers isolated directly from Alzheimer’s brains impair
synaptic plasticity and memory. Nat Med 14(8): 837–842.
47. Brody DL, Holtzman DM, Active and passive immunotherapy for neurodegen-
erative disorders. Annu Rev Neurosci 31: 175–193.
48. Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, et al. (2000) A
beta peptide vaccination prevents memory loss in an animal model of
Alzheimer’s disease. Nature 408(6815): 982–985.
49. Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, et al. (2000) A beta
peptide immunization reduces behavioural impairment and plaques in a model
of Alzheimer’s disease. Nature 408(6815): 979–982.
50. Lemere CA, Maron R, Selkoe DJ, Weiner HL (2001) Nasal vaccination with
beta-amyloid peptide for the treatment of Alzheimer’s disease. DNA Cell Biol
20(11): 705–711.
51. Weiner HL, Lemere CA, Maron R, Spooner ET, Grenfell TJ, et al. (2000) Nasal
administration of amyloid-beta peptide decreases cerebral amyloid burden in a
mouse model of Alzheimer’s disease. Ann Neurol 48(4): 567–579.
52. Maier M, Seabrook TJ, Lazo ND, Jiang L, Das P, et al. (2006) Short amyloid-
beta (Abeta) immunogens reduce cerebral Abeta load and learning deficits in an
Alzheimer’s disease mouse model in the absence of an Abeta-specific cellular
immune response. J Neurosci 26(18): 4717–4728.
53. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, et al. (2001)
Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and
decreases brain A beta burden in a mouse model of Alzheimer’s disease. Proc
Natl Acad Sci USA 98(15): 8850–8855.
54. Wilcock DM, Rojiani A, Rosenthal A, Subbarao S, Freeman MJ, et al. (2004)
Passive immunotherapy against Abeta in aged APP-transgenic mice reverses
cognitive deficits and depletes parenchymal amyloid deposits in spite of
increased vascular amyloid and microhemorrhage. J Neuroinflammation 1(1):
24.
55. Dodart JC, Bales KR, Gannon KS, Greene SJ, DeMattos RB, et al. (2002)
Immunization reverses memory deficits without reducing brain Abeta burden in
Alzheimer’s disease model. Nat Neurosci 5(5): 452–457.
56. Mohajeri MH, Saini K, Schultz JG, Wollmer A, Hock C, et al. (2002) Passive
immunization against beta-amyloid peptide protects central nervous system
(CNS) neurons from increased vulnerability associated with an Alzheimer’s
disease-causing mutation. J Biol Chem 277(36): 33012–33017.
57. Dickstein DL, Biron KE, Ujiie M, Pfeifer CG, Jeffries AR, et al. (2006) Abeta
peptide immunization restores blood-brain barrier integrity in Alzheimer
disease. Faseb J 20(3): 426–433.
58. Buttini M, Masliah E, Barbour R, Grajeda H, Motter R, et al. (2005) Beta-
amyloid immunotherapy prevents synaptic degeneration in a mouse model of
Alzheimer’s disease. J Neurosci 25(40): 9096–9101.
59. Rozga M, Kloniecki M, Jablonowska A, Dadlez M, Bal W, The binding constant
for amyloid Abeta40 peptide interaction with human serum albumin. Biochem
Biophys Res Commun 364(3): 714–718.
60. Thorne RG, Frey II WH (2001) Delivery of neurotrophic factors to the central
nervous system: pharmacokinetic considerations. Clin Pharmacokinet 40(12):
907–946.
61. Levites Y, Smithson LA, Price RW, Dakin RS, Yuan B, et al. (2006) Insights into
the mechanisms of action of anti-Abeta antibodies in Alzheimer’s disease mouse
models. Faseb J 20(14): 2576–2578.
62. Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, et al. (2003)
Neuropathology of human Alzheimer disease after immunization with amyloid-
beta peptide: a case report. Nat Med 9(4): 448–452.
63. Chen XQ (1998) Delivery of Nerve Growth Factor to the brain via the olfactory
pathway. J. Alzheimer’s Dis 1(1): 35–44.
64. Prada CM, Garcia-Alloza M, Betensky RA, Zhang-Nunes SX, Greenberg SM,
et al. (2007) Antibody-mediated clearance of amyloid-beta peptide from cerebral
amyloid angiopathy revealed by quantitative in vivo imaging. J Neurosci 27(8):
1973–1980.
65. Schroeter S, Khan K, Barbour R, Doan M, Chen M, et al. (2008)
Immunotherapy reduces vascular amyloid-beta in PDAPP mice. J Neurosci
28(27): 6787–6793.
66. Thorne RG, Hanson LR, Ross TM, Tung D, Frey II WH (2008) Delivery of
Interferon-b to the monkey nervous system following intranasal administration.
Neuroscience 152(3): 785–797.
67. Dhuria SV, Hanson LR, Frey II WH (2009) Intranasal drug targeting of
Hypocretin-1 (Orexin-A) to the Central Nervous System. J Pharm Sci 98(7):
2501–2515.
68. Deadwyler SA, Porrino L, Siegel JM, Hampson RE (2007) Systemic and nasal
delivery of Orexin-A (Hypocretin-1) reduces the effects of sleep deprivation on
cognitive performance in nonhuman primates. J Neurosci 27(52): 14239–14247.
69. Reger MA, Watson GS, Green PS, Baker LD, Cholerton B, et al. (2008)
Intranasal Insulin administration dose-dependently modulates verbal memory
and plasma amyloid-b in memory-impaired older adults. J Alzheimer’s Dis 13(3):
323–331.
70. Reger MA, Watson GS, Green PS, Wilkinson CW, Baker LD, et al. (2008)
Intranasal Insulin improves cognition and modulates b-amyloid in early AD.
Neurology 70: 440–448.
Intranasal Treatment with Anti-Ab42 scFv
PLoS ONE | www.plosone.org 13 April 2011 | Volume 6 | Issue 4 | e18296
